Novartis' Next Gen Diagnostics Group Puts NGS to Work for Oncology Drug, Dx Development | GenomeWeb

A little over a year after setting up shop, the Next Generation Diagnostics group at the Novartis Institutes for Biomedical Research in Cambridge, Mass., has begun to support the drug maker's oncology research with a variety of next-generation sequencing-based approaches.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.